Related Experiment Video

Updated: May 25, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer

Karen L Reckamp1

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, 1500 E. Duarte Rd., MOB 1001, Duarte, CA 91010, USA. kreckamp@coh.org

Cancer Letters
|February 7, 2012
PubMed

Insights

Antiangiogenic therapies targeting tumor vasculature show promise for non-small cell lung cancer (NSCLC) second-line treatment. Ongoing studies are evaluating antibodies, small molecules, and vascular-disrupting agents to improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tumor vasculature is a validated therapeutic target, particularly with the success of bevacizumab in non-small cell lung cancer (NSCLC).
  • Second-line therapies offer a critical opportunity to enhance overall survival and quality of life beyond best supportive care in NSCLC patients.

Purpose of the Study:

  • To review the current landscape of angiogenesis inhibition strategies in NSCLC.
  • To focus on the application of these antiangiogenic therapies in the second-line treatment setting.

Main Methods:

  • Review of current phase II and phase III clinical studies evaluating antiangiogenic treatments in NSCLC.
  • Analysis of various antiangiogenic therapeutic classes, including antibodies, small molecule inhibitors, and vascular-disrupting agents.

Main Results:

  • Ongoing clinical trials are actively investigating the efficacy of antiangiogenic treatments as second-line options for NSCLC.
  • Results from these pivotal studies are anticipated and will inform future treatment guidelines.

Conclusions:

  • Angiogenesis inhibition represents a significant and evolving therapeutic avenue for NSCLC management.
  • The development and evaluation of novel antiangiogenic agents in the second-line setting hold considerable potential for improving patient outcomes.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...